Phase II study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy in patients with muscle-invasive urothelial cancer (MI-UC): Pathologic and radiologic response, serum tumor markers, and DNA excision repair pathway biomarkers in relation to disease-free survival (DFS) Meeting Abstract


Authors: Qu, A. Q.; Jacobus, S. J.; Signoretti, S.; Stack, E. C.; Krajewski, K. M.; Rosenberg, J. E.; Choueiri, T. K.
Abstract Title: Phase II study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy in patients with muscle-invasive urothelial cancer (MI-UC): Pathologic and radiologic response, serum tumor markers, and DNA excision repair pathway biomarkers in relation to disease-free survival (DFS)
Meeting Title: 49th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 31
Issue: 15 Suppl.
Meeting Dates: 2013 May 31-Jun 4
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2013-05-20
Language: English
ACCESSION: WOS:000335419601544
PROVIDER: wos
DOI: 10.1200/jco.2013.31.15_suppl.4530
Notes: Meeting Abstract: 4530 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jonathan Eric Rosenberg
    510 Rosenberg